Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nurix Therapeutics Inc's Business Segments
Nurix Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
License Revenue
Total Revenue
$ 9
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License Revenue0%
- Collaboration Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License Revenue | $ 30 | - |
| Collaboration Revenue | $ 15 | - |
Revenue by Product & Service Category - FY
- Collaboration Revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 9 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- License Revenue0%
- Collaboration Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License Revenue | $ 30 | - |
| Collaboration Revenue | $ 15 | - |
Description of Nurix Therapeutics Inc
Nurix Therapeutics Inc is a biopharmaceutical company that specializes in developing targeted protein modulation drugs for the treatment of various diseases. The company was founded in 2013, and is headquartered in San Francisco, California.
Nurix's technology platform is based on the discovery and understanding of the ubiquitin proteasome system (UPS), a naturally occurring biological process that regulates the degradation and recycling of proteins in cells. The company's approach involves using small molecule drugs to precisely target proteins within the UPS, thereby treating diseases at their root cause.
Nurix's research and development programs are focused on two key areas: oncology and immunology. Within oncology, the company is developing drugs to target specific cancer-causing genes, with the goal of creating more effective and targeted cancer therapies. In immunology, the company is developing drugs to treat inflammatory diseases, such as autoimmune disorders and graft-versus-host disease.
One of Nurix's most promising drug candidates is NX-2127, a small molecule drug designed to degrade the protein BCL-6, which is involved in the development of several types of lymphoma. The company has completed preclinical studies on NX-2127, and is currently advancing the drug into Phase 1 clinical trials.
Nurix has partnerships and collaborations with several major pharmaceutical companies, including Gilead Sciences, Eli Lilly, and Sanofi. These collaborations allow Nurix to leverage its expertise in protein modulation to develop new therapies in areas such as oncology, immunology, and neurology.
Overall, Nurix Therapeutics Inc is a cutting-edge biopharmaceutical company that is revolutionizing the treatment of diseases through its innovative protein modulation technology platform. With a focus on oncology and immunology, the company is well-positioned to make a significant impact on the healthcare industry in the years to come.
Nurix's technology platform is based on the discovery and understanding of the ubiquitin proteasome system (UPS), a naturally occurring biological process that regulates the degradation and recycling of proteins in cells. The company's approach involves using small molecule drugs to precisely target proteins within the UPS, thereby treating diseases at their root cause.
Nurix's research and development programs are focused on two key areas: oncology and immunology. Within oncology, the company is developing drugs to target specific cancer-causing genes, with the goal of creating more effective and targeted cancer therapies. In immunology, the company is developing drugs to treat inflammatory diseases, such as autoimmune disorders and graft-versus-host disease.
One of Nurix's most promising drug candidates is NX-2127, a small molecule drug designed to degrade the protein BCL-6, which is involved in the development of several types of lymphoma. The company has completed preclinical studies on NX-2127, and is currently advancing the drug into Phase 1 clinical trials.
Nurix has partnerships and collaborations with several major pharmaceutical companies, including Gilead Sciences, Eli Lilly, and Sanofi. These collaborations allow Nurix to leverage its expertise in protein modulation to develop new therapies in areas such as oncology, immunology, and neurology.
Overall, Nurix Therapeutics Inc is a cutting-edge biopharmaceutical company that is revolutionizing the treatment of diseases through its innovative protein modulation technology platform. With a focus on oncology and immunology, the company is well-positioned to make a significant impact on the healthcare industry in the years to come.
Nurix Therapeutics Inc is a leading biotechnology firm that specializes in the innovative development of drugs through the targeting of protein degradation pathways, a critical area of cellular regulation. The companys offerings can be comprehensively categorized into two primary segments: Drug Discovery and Development, and Therapeutic Candidates.
1. Drug Discovery and Development:
Nurix Therapeutics employs a sophisticated and proprietary discovery platform designed to reveal potential drug targets through detailed insights into molecular and cellular biology. The various products and services within this segment encompass:
- Proprietary Discovery Platform: This platform integrates advanced methodologies in molecular biology, biochemistry, and computational biology to identify and validate new drug targets. By leveraging high-throughput screening and other bioanalytical techniques, the platform enhances the efficiency and accuracy of drug discovery.
- Medicinal Chemistry: Nurix provides extensive expertise in medicinal chemistry, playing a pivotal role in optimizing potential drug candidates. This includes the rational design and modification of small molecules to enhance their efficacy, selectivity, and pharmacokinetic properties.
- Preclinical Testing: Comprehensive preclinical services are offered to assess the pharmacodynamics, pharmacokinetics, and toxicology of developed candidates. This ensures that only the most promising drug candidates progress to clinical trials, thus maximizing the chances of success in humans.
- Collaborative Research: Nurix engages in collaborative research agreements with academic institutions and pharmaceutical companies, fostering an environment of innovation and shared goals in discovering novel therapeutic strategies.
Therapeutic Candidates:
The therapeutic candidate pipeline of Nurix Therapeutics is particularly focused on groundbreaking therapies for oncology and immunological diseases. Key components of their therapeutic candidates include:
- Protein Degradation Modulators: Nurix stands at the forefront of developing drugs that modulate the function of E3 ligases, which play essential roles in the ubiquitin-proteasome pathway responsible for protein degradation.
- Mechanism: These compounds are designed to specifically target disease-related proteins for degradation. By harnessing the body’s natural cellular processes, they can selectively eliminate harmful proteins, offering a novel approach to treating diseases by restoring normal protein homeostasis.
- Bruton’s Tyrosine Kinase (BTK) Inhibitors: One of the most developed program areas for Nurix involves the development of BTK inhibitors, particularly for treating B-cell malignancies and autoimmune conditions.
- NX-2127: The lead candidate in this category, NX-2127, is undergoing Phase 1 clinical trials. BTK inhibitors have been shown to interfere with the signals that promote the growth and survival of malignant B-cells, thereby providing a targeted approach in the management of these disorders.
- Additional Preclinical Programs: Beyond the highlighted programs, Nurix is actively developing several other projects targeting various E3 ligases and modulators of the ubiquitin-proteasome pathway. These may target distinct diseases or conditions, further broadening their therapeutic scope.
Summary:
In essence, Nurix Therapeutics Inc focuses on delivering exceptional drug discovery and development services while advancing a promising pipeline of therapeutic candidates aimed at treating cancer and immune disorders. Through their expertise in protein degradation pathways, Nurix seeks to innovate and bring to market new therapies that address pressing medical needs, reflecting the companys commitment to transforming the landscape of biotechnology and therapeutic treatment.
1. Drug Discovery and Development:
Nurix Therapeutics employs a sophisticated and proprietary discovery platform designed to reveal potential drug targets through detailed insights into molecular and cellular biology. The various products and services within this segment encompass:
- Proprietary Discovery Platform: This platform integrates advanced methodologies in molecular biology, biochemistry, and computational biology to identify and validate new drug targets. By leveraging high-throughput screening and other bioanalytical techniques, the platform enhances the efficiency and accuracy of drug discovery.
- Medicinal Chemistry: Nurix provides extensive expertise in medicinal chemistry, playing a pivotal role in optimizing potential drug candidates. This includes the rational design and modification of small molecules to enhance their efficacy, selectivity, and pharmacokinetic properties.
- Preclinical Testing: Comprehensive preclinical services are offered to assess the pharmacodynamics, pharmacokinetics, and toxicology of developed candidates. This ensures that only the most promising drug candidates progress to clinical trials, thus maximizing the chances of success in humans.
- Collaborative Research: Nurix engages in collaborative research agreements with academic institutions and pharmaceutical companies, fostering an environment of innovation and shared goals in discovering novel therapeutic strategies.
Therapeutic Candidates:
The therapeutic candidate pipeline of Nurix Therapeutics is particularly focused on groundbreaking therapies for oncology and immunological diseases. Key components of their therapeutic candidates include:
- Protein Degradation Modulators: Nurix stands at the forefront of developing drugs that modulate the function of E3 ligases, which play essential roles in the ubiquitin-proteasome pathway responsible for protein degradation.
- Mechanism: These compounds are designed to specifically target disease-related proteins for degradation. By harnessing the body’s natural cellular processes, they can selectively eliminate harmful proteins, offering a novel approach to treating diseases by restoring normal protein homeostasis.
- Bruton’s Tyrosine Kinase (BTK) Inhibitors: One of the most developed program areas for Nurix involves the development of BTK inhibitors, particularly for treating B-cell malignancies and autoimmune conditions.
- NX-2127: The lead candidate in this category, NX-2127, is undergoing Phase 1 clinical trials. BTK inhibitors have been shown to interfere with the signals that promote the growth and survival of malignant B-cells, thereby providing a targeted approach in the management of these disorders.
- Additional Preclinical Programs: Beyond the highlighted programs, Nurix is actively developing several other projects targeting various E3 ligases and modulators of the ubiquitin-proteasome pathway. These may target distinct diseases or conditions, further broadening their therapeutic scope.
Summary:
In essence, Nurix Therapeutics Inc focuses on delivering exceptional drug discovery and development services while advancing a promising pipeline of therapeutic candidates aimed at treating cancer and immune disorders. Through their expertise in protein degradation pathways, Nurix seeks to innovate and bring to market new therapies that address pressing medical needs, reflecting the companys commitment to transforming the landscape of biotechnology and therapeutic treatment.